0.01Open0.01Pre Close0 Volume29 Open Interest2.50Strike Price0.00Turnover1931.72%IV26.77%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Time Value100Contract SizeAmericanOptions Type0.0769Delta0.4699Gamma198.00Leverage Ratio-0.9098Theta0.0000Rho15.23Eff Leverage0.0000Vega
Xeris Pharmaceuticals Stock Discussion
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
No comment yet